Kepler Vision Technologies Unveils Innovative Kepler Night Nurse Lying Position Detection to Combat Pressure Ulcers

Kepler Vision Technologies, a pioneering leader in healthcare AI solutions, is proud to introduce its ground-breaking feature, the Kepler Night Nurse Lying Position Detection. This innovative technology, offers a powerful solution to the pressing issue of pressure ulcers, commonly known as bedsores.

Pressure ulcers pose a significant threat to patients, with statistics indicating that over 60 percent of patients face the risk of developing these painful sores, with approximately 250 people losing their lives each year due to complications arising from pressure ulcers, according to recent research.

The Kepler Night Nurse Lying Position Detection augments the existing suite of features, including fall detection and prevention modules. This new addition is designed to empower healthcare professionals in their tireless efforts to prevent and mitigate the occurrence of bedsores.

Pressure ulcers result from various factors, primarily prolonged pressure on the skin or shearing forces. Vulnerable patients include elderly residents in nursing homes and individuals recovering from surgery who are confined to their beds. Given that pressure ulcers often heal slowly and are prone to recurrence, prevention is paramount.

Healthcare providers employ multiple interventions to avert pressure ulcers, with repositioning patients as a central strategy. Additionally, healthcare staff assess mattress suitability and maximize bed capabilities. However, these interventions demand considerable time and attention from healthcare workers. Some patients are unable to change positions independently, potentially disrupting their vital sleep, leading to fatigue and restlessness.

The Kepler Night Nurse Lying Position Detection empowers healthcare professionals with critical information about patients at an elevated risk of developing pressure ulcers. By continuously monitoring patients’ sleep positions, the Kepler module offers timely insights, indicating when manual position adjustments are required.

This revolutionary feature not only saves a significant amount of time—manual patient turning can take up to 20 minutes and must occur every 2 to 4 hours—but also reduces healthcare costs. The financial burden associated with caring for patients with pressure ulcers ranges from tens to hundreds of euros per patient per day, depending on the severity of the condition.

Kepler Vision Technologies is dedicated to transforming healthcare by leveraging advanced AI solutions, and the Kepler Night Nurse Lying Position Detection is a testament to the commitment to enhancing patient care, alleviating the workload of healthcare professionals, and ultimately improving the quality of life for those under their care.


Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.

By using this website you agree to accept Medical Device News Magazine Privacy Policy